Τίτλος:
The influence of levodopa and the COMT inhibitor on serum vitamin B12 and folate levels in Parkinson's disease patients
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Serum folate and vitamin B12 levels were measured in 67 consecutive Parkinson's disease patients treated either with levodopa + dopa decarboxylase inhibitor (DDC-i) plus catechol-O-methyltransferase inhibitors (COMT-i) or only with levodopa + DDC-i. The data were compared to 67 age-matched controls. Our findings show that levodopa-treated Parkinson's disease patients have low folate (p < 0.0007) and vitamin B12 levels (p < 0.0003). They also demonstrate that the addition of a COMT-i to levodopa + DDC-i treatment causes lower serum vitamin B12 (p < 0.03) and folate levels (p < 0.005) than levodopa + DDC-i treatment alone. We suggest supplementary treatment with vitamin B12 and folic acid in these situations. Copyright © 2007 S. Karger AG.
Συγγραφείς:
Triantafyllou, N.I.
Kararizou, E.
Angelopoulos, E.
Tsounis, S.
Boufidou, F.
Evangelopoulos, M.E.
Nikolaou, C.
Vassilopoulos, D.
Περιοδικό:
European Neurology
Λέξεις-κλειδιά:
benserazide plus levodopa; catechol methyltransferase inhibitor; cyanocobalamin; DOPA decarboxylase inhibitor; entacapone; folic acid, adult; aged; article; comparative study; controlled study; female; folic acid blood level; human; major clinical study; male; Parkinson disease; priority journal; vitamin blood level, Aged; Analysis of Variance; Antiparkinson Agents; Case-Control Studies; Catechols; Female; Folic Acid; Humans; Immunoassay; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Vitamin B 12
